Nothing new today. The sweep found no new drug approvals, no label changes and no safety communications in diabetes.
The most recent relevant activity was on 11 August, when the US regulator posted six supplemental actions on already-marketed metformin fixed-dose combinations: Jentadueto and Jentadueto XR, Trijardy XR and Synjardy from one manufacturer, and Zituvimet and Zituvimet XR from another. These are supplements to existing applications rather than new approvals, and none introduces a new molecular entity. The postings record that an action was taken, not what it contained, so nothing in them tells you that a prescribing detail has changed.
There is nothing to do. The regulatory change still working its way through practice is the 2026 US dyslipidaemia guideline covered earlier this week, under which diabetes remains a statin indication regardless of any calculated risk score. A quiet day is worth reporting as quiet: it means the prescribing decisions you made last week still stand, and no patient needs to be recalled on the strength of anything published since.
- No prescription needs to change as a result of today's sweep.
- The six US supplemental actions on 11 August were all on existing metformin combinations; none was a new approval.
- If you use these combination products, check the current prescribing information at the next reorder rather than assuming a change was made.
- Diabetes continues to trigger statin eligibility independent of any calculated risk score under the 2026 US dyslipidaemia guidance.
- Indian brand names and availability differ from the US listings; check the local product insert rather than the US label.
The statistics, in plain English
There are no numbers in today's regulatory news, and that absence is itself the finding. Six supplemental applications against zero new approvals is an unremarkable result for a single sweep, and it should not be read as anything having been withheld, delayed or hidden. Supplemental applications are the routine administrative traffic of drugs already on the market; new molecular entities are rare events, and most weeks contain none.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free